Melanoma Matters23 Joulu 2024

Ep 56: Best of 2024: ASCO

Summary

Verbalizing punctuation for laughs...background wood noises ... and out of office replies get things started.

In this episode of Melanoma Matters, hosts James Larkin and Sapna Patel record their first in a series of "Best of 2024" and review highlights from the ASCO Annual Meeting. They focus on 4 significant trials: NADINA, COMBI-AD, KEYNOTE 942, and RELATIVITY 048.

James & Sapna discuss the implications of these studies on the melanoma landscape, the importance of long-term follow-up data, and share some light-hearted moments about out-of-office messages.

Keywords

ASCO 2024, melanoma, NADINA trial, neoantigen therapy, checkpoint blockade, out of office messages, long-term follow-up, immunotherapy

Takeaways

Out-of-office messages can be creative and memorable.

The NADINA trial showed a high major pathologic response rate of 60%.

Patient inclusion and trial design in clinical trials can critically affect outcomes (COMBI-AD).

The KEYNOTE 942 trial demonstrated encouraging trends for overall survival.

Triplet checkpoint blockade shows promising PFS results (RELATIVITY 048).

Titles

ASCO 2024 Highlights: Melanoma Trials Reviewed

NADINA, COMBI-AD, KN 942, RELA 048

Chapters

00:00 Introduction and Icebreakers

06:24 ASCO 2024 Highlights: NADINA Trial

13:39 Long-Term Follow-Up: COMBI-AD Study

21:16 Individualized Neoantigen Therapy: KEYNOTE 942

30:23 Triplet Checkpoint Blockade: RELATIVITY 048

31:11 Fact Check Best of 2024: ASCO

31:16 FDA Guidelines on Phase 3 Trials (Listening Series)

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(93)

Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)

Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell ShortHobbies - James wishes he was surfing more This episode breaks down three negative adjuvant melanoma trials testing combination immunothe...

1 Syys 22min

Ep 86: Teaser Tudriqev (RP1) FDA Approval

James asks the big question

25 Elo 10s

Ep 87: INTerpath-001 Press Release - August 2026

In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualize...

25 Elo 12min

Ep 86: Tudriqev (RP1) FDA Approval

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-VThey discuss the FDA Cell and Gene Therapy Advisory Committee's review of the si...

25 Elo 52min

Ep 85: Surgical considerations for TIL

In this episode, Sapna and James talk tv shows - The Gambler and His Cowboys, Brassic... They discuss the paper from NKI on surgical considerations for TIL harvest published in BJS in 2025. Topics of ...

28 Heinä 29min

Ep 84: Merlin CP-GEP and Castle i31-SLNB tests

In this episode, the chin dimple is front and center. James explains the wizarding home of Tintagel in Cornwall to Sapna, situated on a lovely promontory. This episode explores the latest evidence on ...

24 Heinä 35min

Ep 83: Guest Megan Othus and Time of Day Administration

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...

24 Kesä 40min

Ep 82: Best of ASCO: 2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...

13 Kesä 1h 4min